Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04171700 · OUTCOME

Number of Participants Experiencing Treatment-emergent Adverse Events

A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes · Source last updated 2023-10-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
From first dose of study drug until disease progression (up to approximately 2 years)

Analysis population: Safety Population - all enrolled participants who received at least 1 dose of protocol-specified treatment.

Groups in this outcome

Rucaparib Cohort A

Participants with a deleterious mutation in one of the following genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.

Rucaparib Cohort B

Participants with a deleterious mutation in one of the following genes: BARD1, BRIP1, FANCA, NBN, RAD51, or RAD51B.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Rucaparib Cohort A63
Rucaparib Cohort B20

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Rucaparib Cohort A63Not reportedNot reportedNot reportedNot reported
Rucaparib Cohort B20Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        63
      2. group Id
        OG001
        value
        20
denoms
  1. counts
    1. group Id
      OG000
      value
      63
    2. group Id
      OG001
      value
      20
    units
    Participants
groups
  1. description
    Participants with a deleterious mutation in one of the following genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.
    id
    OG000
    title
    Rucaparib Cohort A
  2. description
    Participants with a deleterious mutation in one of the following genes: BARD1, BRIP1, FANCA, NBN, RAD51, or RAD51B.
    id
    OG001
    title
    Rucaparib Cohort B
param Type
COUNT_OF_PARTICIPANTS
population Description
Safety Population - all enrolled participants who received at least 1 dose of protocol-specified treatment.
reporting Status
POSTED
time Frame
From first dose of study drug until disease progression (up to approximately 2 years)
title
Number of Participants Experiencing Treatment-emergent Adverse Events
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice